Inhibikase Therapeutics (IKT) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -38.56% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 62.15% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -50.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.28% |
| Mar 31, 2026 | -55.83% |
| Dec 31, 2025 | -47.02% |
| Sep 30, 2025 | -41.63% |
| Jun 30, 2025 | -32.66% |
| Mar 31, 2025 | -46.52% |
| Dec 31, 2024 | -36.88% |
| Sep 30, 2024 | -9.23% |
| Jun 30, 2024 | -24.20% |
| Mar 31, 2024 | -21.95% |
| Dec 31, 2023 | -53.90% |
| Sep 30, 2023 | -92.30% |
| Jun 30, 2023 | -144.98% |
| Mar 31, 2023 | -104.98% |